Literature DB >> 18997997

Clinical aspects of melatonin.

Russel J Reiter1, Ahmet Korkmaz.   

Abstract

Melatonin is produced in the human pineal gland, particularly at night, with the circadian rhythm of blood melatonin levels closely paralleling its production within the pineal gland. Light exposure at night, or rapid transmeridian travel severely compromises the circadian production of melatonin. The disturbed melatonin rhythm contributes to jet lag and sleep inefficiency, both of which are improved by melatonin administration. Melatonin is also a highly effective direct free radical scavenger and antioxidant. In this capacity, melatonin reduces experimental cataractogenesis, traumatic injury to the spinal cord and brain, and protects against oxidative damage to neurons and glia in models of stroke, Parkinsonism, and Alzheimer's disease. Additionally, melatonin and its metabolites are highly effective in protecting against ionizing radiation. Finally, melatonin may be a treatment for hypertension. Melatonin's high efficacy, its high safety profile, and its virtual lack of toxicity make it of interest in clinical medicine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997997

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  10 in total

1.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

2.  Effects of antenatal, postpartum and post-weaning melatonin supplementation on blood pressure and renal antioxidant enzyme activities in spontaneously hypertensive rats.

Authors:  S K Lee; K N S Sirajudeen; Arunkumar Sundaram; Rahimah Zakaria; H J Singh
Journal:  J Physiol Biochem       Date:  2011-01-06       Impact factor: 4.158

Review 3.  Extrapineal melatonin: sources, regulation, and potential functions.

Authors:  Darío Acuña-Castroviejo; Germaine Escames; Carmen Venegas; María E Díaz-Casado; Elena Lima-Cabello; Luis C López; Sergio Rosales-Corral; Dun-Xian Tan; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2014-02-20       Impact factor: 9.261

4.  Melatonin metabolism in the central nervous system.

Authors:  Rüdiger Hardeland
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

5.  The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension.

Authors:  Monika Możdżan; Michał Możdżan; Maciej Chałubiński; Katarzyna Wojdan; Marlena Broncel
Journal:  Arch Med Sci       Date:  2014-08-29       Impact factor: 3.318

6.  Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits.

Authors:  Xiaowen Cheng; Yufeng Wan; Yuanhong Xu; Qing Zhou; Yuan Wang; Huaqing Zhu
Journal:  Mol Med Rep       Date:  2014-10-23       Impact factor: 2.952

7.  Association between nighttime-daytime sleep patterns and chronic diseases in Chinese elderly population: a community-based cross-sectional study.

Authors:  Shuo Zhang; Li Xie; Herbert Yu; Weituo Zhang; Biyun Qian
Journal:  BMC Geriatr       Date:  2019-04-29       Impact factor: 3.921

8.  Melatonin anticancer effects: review.

Authors:  Giuseppe Di Bella; Fabrizio Mascia; Luciano Gualano; Luigi Di Bella
Journal:  Int J Mol Sci       Date:  2013-01-24       Impact factor: 5.923

9.  Effect of melatonin on the functional recovery from experimental traumatic compression of the spinal cord.

Authors:  A Schiaveto-de-Souza; C A da-Silva; H L A Defino; E A Del Bel
Journal:  Braz J Med Biol Res       Date:  2013-04-12       Impact factor: 2.590

10.  The melatonin metabolite N1-acetyl-5-methoxykynuramine facilitates long-term object memory in young and aging mice.

Authors:  Hikaru Iwashita; Yukihisa Matsumoto; Yusuke Maruyama; Kazuki Watanabe; Atsuhiko Chiba; Atsuhiko Hattori
Journal:  J Pineal Res       Date:  2020-11-20       Impact factor: 13.007

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.